157 related articles for article (PubMed ID: 38064927)
1. Quantitative prediction of transporter-mediated drug-drug interactions using the mechanistic static pharmacokinetic (MSPK) model.
Asano S; Kurosaki C; Mori Y; Shigemi R
Drug Metab Pharmacokinet; 2024 Feb; 54():100531. PubMed ID: 38064927
[TBL] [Abstract][Full Text] [Related]
2. Prediction of pharmacokinetics and drug-drug interactions when hepatic transporters are involved.
Li R; Barton HA; Varma MV
Clin Pharmacokinet; 2014 Aug; 53(8):659-78. PubMed ID: 25056496
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic Drug-Drug Interactions with Drugs Approved by the US Food and Drug Administration in 2020: Mechanistic Understanding and Clinical Recommendations.
Yu J; Wang Y; Ragueneau-Majlessi I
Drug Metab Dispos; 2022 Jan; 50(1):1-7. PubMed ID: 34620694
[TBL] [Abstract][Full Text] [Related]
4. Studying the right transporter at the right time: an
Elsby R; Atkinson H; Butler P; Riley RJ
Expert Opin Drug Metab Toxicol; 2022 Oct; 18(10):619-655. PubMed ID: 36205497
[TBL] [Abstract][Full Text] [Related]
5. Predicting the Drug-Drug Interaction Mediated by CYP3A4 Inhibition: Method Development and Performance Evaluation.
Ren HC; Sai Y; Chen T; Zhang C; Tang L; Yang CG
AAPS J; 2021 Dec; 24(1):12. PubMed ID: 34893925
[TBL] [Abstract][Full Text] [Related]
6. Quantitative prediction of OATP1B-mediated drug-drug interactions using endogenous biomarker coproporphyrin I.
Takubo H; Bessho K; Watari R; Shigemi R
Xenobiotica; 2022 Apr; 52(4):397-404. PubMed ID: 35638858
[TBL] [Abstract][Full Text] [Related]
7. Dealing with the complex drug-drug interactions: towards mechanistic models.
Varma MV; Pang KS; Isoherranen N; Zhao P
Biopharm Drug Dispos; 2015 Mar; 36(2):71-92. PubMed ID: 25545151
[TBL] [Abstract][Full Text] [Related]
8. Transporter-Enzyme Interplay: Deconvoluting Effects of Hepatic Transporters and Enzymes on Drug Disposition Using Static and Dynamic Mechanistic Models.
Varma MV; El-Kattan AF
J Clin Pharmacol; 2016 Jul; 56 Suppl 7():S99-S109. PubMed ID: 27385183
[TBL] [Abstract][Full Text] [Related]
9. In Vitro Assessment of Transporter Mediated Perpetrator DDIs for Several Hepatitis C Virus Direct-Acting Antiviral Drugs and Prediction of DDIs with Statins Using Static Models.
Chu X; Chan GH; Houle R; Lin M; Yabut J; Fandozzi C
AAPS J; 2022 Mar; 24(3):45. PubMed ID: 35314909
[TBL] [Abstract][Full Text] [Related]
10. Physiologically Based Pharmacokinetic Modeling of Rosuvastatin to Predict Transporter-Mediated Drug-Drug Interactions.
Hanke N; Gómez-Mantilla JD; Ishiguro N; Stopfer P; Nock V
Pharm Res; 2021 Oct; 38(10):1645-1661. PubMed ID: 34664206
[TBL] [Abstract][Full Text] [Related]
11. Assessment of algorithms for predicting drug-drug interactions via inhibition mechanisms: comparison of dynamic and static models.
Guest EJ; Rowland-Yeo K; Rostami-Hodjegan A; Tucker GT; Houston JB; Galetin A
Br J Clin Pharmacol; 2011 Jan; 71(1):72-87. PubMed ID: 21143503
[TBL] [Abstract][Full Text] [Related]
12. Critical Impact of Drug-Drug Interactions via Intestinal CYP3A in the Risk Assessment of Weak Perpetrators Using Physiologically Based Pharmacokinetic Models.
Yamada M; Inoue SI; Sugiyama D; Nishiya Y; Ishizuka T; Watanabe A; Watanabe K; Yamashita S; Watanabe N
Drug Metab Dispos; 2020 Apr; 48(4):288-296. PubMed ID: 31996361
[TBL] [Abstract][Full Text] [Related]
13. Strong Pharmacokinetic Drug-Drug Interactions With Drugs Approved by the US Food and Drug Administration in 2021: Mechanisms and Clinical Implications.
Yu J; Wang Y; Ragueneau-Majlessi I
Clin Ther; 2022 Nov; 44(11):1536-1544. PubMed ID: 36210218
[TBL] [Abstract][Full Text] [Related]
14. Physiologically-based Pharmacokinetic (PBPK) Modelling of Transporter Mediated Drug Absorption, Clearance and Drug-drug Interactions.
Taskar KS; Harada I; Alluri RV
Curr Drug Metab; 2021; 22(7):523-531. PubMed ID: 33397250
[TBL] [Abstract][Full Text] [Related]
15. Quantitative prediction of renal transporter-mediated clinical drug-drug interactions.
Feng B; Hurst S; Lu Y; Varma MV; Rotter CJ; El-Kattan A; Lockwood P; Corrigan B
Mol Pharm; 2013 Nov; 10(11):4207-15. PubMed ID: 24066726
[TBL] [Abstract][Full Text] [Related]
16. In vitro and physiologically-based pharmacokinetic based assessment of drug-drug interaction potential of canagliflozin.
Mamidi RNVS; Dallas S; Sensenhauser C; Lim HK; Scheers E; Verboven P; Cuyckens F; Leclercq L; Evans DC; Kelley MF; Johnson MD; Snoeys J
Br J Clin Pharmacol; 2017 May; 83(5):1082-1096. PubMed ID: 27862160
[TBL] [Abstract][Full Text] [Related]
17. Evaluation and Quantitative Prediction of Renal Transporter-Mediated Drug-Drug Interactions.
Feng B; Varma MV
J Clin Pharmacol; 2016 Jul; 56 Suppl 7():S110-21. PubMed ID: 27385169
[TBL] [Abstract][Full Text] [Related]
18. Drug-Drug Interaction Risk Assessment of Esaxerenone as a Perpetrator by In Vitro Studies and Static and Physiologically Based Pharmacokinetic Models.
Yamada M; Ishizuka T; Inoue SI; Rozehnal V; Fischer T; Sugiyama D
Drug Metab Dispos; 2020 Sep; 48(9):769-777. PubMed ID: 32616542
[TBL] [Abstract][Full Text] [Related]
19. Semi-mechanistic physiologically-based pharmacokinetic modeling of clinical glibenclamide pharmacokinetics and drug-drug-interactions.
Greupink R; Schreurs M; Benne MS; Huisman MT; Russel FG
Eur J Pharm Sci; 2013 Aug; 49(5):819-28. PubMed ID: 23806476
[TBL] [Abstract][Full Text] [Related]
20. Transporter-mediated drug--drug interactions involving OATP substrates: predictions based on in vitro inhibition studies.
Yoshida K; Maeda K; Sugiyama Y
Clin Pharmacol Ther; 2012 Jun; 91(6):1053-64. PubMed ID: 22534868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]